Impact of local anesthetics on epigenetics in cancer

Bezu, Lucillia; Kepp, Oliver; Kroemer, Guido

doi:10.3389/fonc.2022.849895

Cited by 5 publications

(2 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following primary tumor excision with local anesthetic as opposed to merely general anesthesia, several retrospective clinical investigations have shown a significant improvement in overall survival and a decrease in recurrence rates. The observed epidemiological data lends support to the hypothesis that local anesthesia may possess anticancer properties [9].…”

Section: Local Anestheticssupporting

confidence: 77%

The influence of immunology and anesthesia on cancer

Qin

2023

TNS

View full text Add to dashboard Cite

Oncogenesis, characterized by abnormal cell proliferation, poses a global concern due to its high morbidity and mortality rates. Surgical interventions, often involving anesthetics, are common in cancer patients. Understanding their effects can lead to breakthroughs in cancer treatment, especially in the context of immunotherapy. Researchers have identified how the immune system and anesthetics affect the recurrence and metastasis of cancer. Immunotherapy, which utilizes the immune system to target tumors, has shown promise in clinical trials. In the adaptive immune system, T cells and B cells play significant roles in tumor detection and elimination. The immune system consists of innate and adaptive systems that help fight infections and diseases. Pattern recognition receptors (PRRs) trigger non-specific inflammatory responses in the innate immune system. Anesthesia is commonly administered to cancer patients, but different methods and groups of anesthesia exert divergent effects on oncological progression. Some studies have suggested a potential correlation between specific inhalation anesthetics and the modulation of tumor cell proliferation and apoptosis. Considering the interaction between the immune system and anesthetics, different combinations have the potential to either promote or inhibit cancer metastasis. Further exploration of these interactions is crucial for optimizing the administration of anesthesia in cancer patients and maximizing the efficacy of immunotherapy. This review sheds light on the complex interplay between immunotherapy, anesthesia, and cancer progression, providing valuable insights for future advancements in cancer treatment strategies.

show abstract

Section: Local Anestheticssupporting

confidence: 77%

The influence of immunology and anesthesia on cancer

Qin

2023

TNS

View full text Add to dashboard Cite

show abstract

“…Numerous studies have shown that the perioperative use of local anesthetics can be bene t to cancer patients and have been demonstrated to reduce the risk of metastasis and recurrence for various cancers in vivo or vitro experiments [22][23][24]. In particular, the amide-linked local anesthetics have been shown to directly inhibit tumor growth, proliferation, and invasion.…”

Section: Discussionmentioning

confidence: 99%

Ropivacaine enhanced the cisplatin-sensitivity of Human colorectal cancer cells by accelerating ROS-meditated apoptosis and ferroptosis

Zhang

Zeng

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

The failure of cisplatin treatment to human colorectal cancer due to cisplatin-sensitivity reduced, it’s necessary to find the new adjuvant agents to increase the cisplatin-sensitivity. Ropivacaine has been demonstrated to inhibit the proliferation and migration of variety of cancer cells, however, it remains unclear whether it could increase the cisplatin sensitivity of colorectal cancer cells. The cisplatin-resistant cell line for colorectal cancer named LOVO/DDP cells were established by repeated induction of different concentration of cisplatin, the cell viability, proliferation, migration, and apoptosis were assessed by Colony-forming assay, Transwell assay, Wound Healing and Annexin V/PI flow cytometry; JC-1 and ROS detection kits were used to determine the levels of mitochondrial membrane potential and reactive oxygen species (ROS). The expression of MMP-9, Nrf-2, GPX4, SLC7A11, SIRT1 proteins were detected by Western-blot and immunofluorescence. Compared with the control group, the activity of LOVO cells decreased significantly and that in LOVO/DDP cells decreased slightly with the increase of cisplatin. After the treatment of ropivacaine combined with cisplatin, the LOVO/DDP cells viability was significantly decreased than cisplatin alone (P<0.01). Compared with cisplatin alone treatment group, the proliferation and migration of LOVO cells and LOVO/DDP cells were significantly reduced in combined group. Ropivacaine combined with cisplatin enhanced apoptosis, the production of ROS, induced mitochondrial dysfunction, and down-regulated anti-ferroptosis and SIRT1 proteins. Those above results demonstrated that ropivacaine could increase the chemosensitivity of cisplatin-resistant human colon cancer cells, and its mechanism may be through promoting cancer cell apoptosis and ferroptosis.

show abstract